tbuckley/cabot-search huggingface dataset:
Prophylactic Infusion Of Multi-Virus Specific T Cells For Management Of Viral Reactivation and Infection In Patients Post Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Authors: Chun Kei Kris Ma, Emily Blyth, Leighton Clancy, Renee Simms, Jane Burgess, Kenneth P. Micklethwaite, David Gottlieb
Journal: Blood (2013)
Whole Genome Sequencing of Therapy-Related Acute Myeloid Leukemia
Authors: Giridharan Ramsingh, Dong Shen, Tamara Lamprecht, Sharon Heath, Robert S. Fulton, Elaine R. Mardis, Li Ding, Peter Westervelt, John S. Welch, Matthew J. Walter, Timothy Graubert, John F. DiPersio, Timothy J. Ley, Richard K Wilson, Daniel C. Link
Journal: Blood (2012)
DA-EPOCH-R Is Highly Effective in Both BCL-6+ and BCL-6− Untreated De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Study Update and Analysis of Survival Outcomes for Multiple Biomarkers.
Authors: Wyndham H. Wilson, Kieron Dunleavy, Stefania Pittaluga, Nicole Grant, Margaret Shovlin, Seth Steinberg, Mark Raffeld, Louis Staudt, Elaine S. Jaffe, John Janik
Journal: Blood (2006)
Targeting Clotting Factor VIII Plasma Values in the Perioperative Setting in Hemophilia a: “Tackling a Moving Target” (“OPTI-CLOT” Studies)
Authors: Janske Lock, Hendrika C.A.M. Hazendonk, Ron A.A. Mathôt, Karina Meijer, Marjolein Peters, Paul Brons, Felix J.M. Van der Meer, Hannan Bouzariouh, Mariette H.E. Driessens, Karin Fijnvandraat, Frank W.G. Leebeek, Marjon H. Cnossen
Journal: Blood (2014)
FRI0623-HPR Kinesiophobia Affects Range of Knee Flexion at Early Stage Following Anterior Cruciate Ligament Reconstruction
Authors: I. Demirbüken, B. Özgül, E. Arıkan, E. Tonga, M.G. Polat
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> One of the most common complications following anterior cruciate ligament (ACL) reconstruction in sport rehabilitation is loss of knee motion (1). A fear of re-injury of ACL may contribute limitations of knee functions in terms of range of motions during rehabilitation process (2). Some athletes are not able to return to their pre-injury level due to loss of knee function and fear of motion in other words kinesiophobia. <h3>Objectives</h3> To investigate the relationship between range of motion (ROM) of the knee which is an important target in rehabilitation and kinesiophobia degree following ACL reconstruction in professional athletes. <h3>Methods</h3> The study was carried out with 14 certified athletes (8 male and 6 female, mean age: 21.5±5.86 years; mean body weight: 68.7±15.2 kg; mean height: 177.5±10.3 cm) who had unilateral ACL reconstruction and started post-op physiotherapy treatment participated in the study. All assessments were performed at 15th day following reconstruction. Kinesiophobia degrees of the athletes were assessed with Tampa Kinesiophobia Scale. A high score obtained from the scale indicates a high degree of kinesiophobia. Active and passive flexion degrees of knee joint were measured by using goniometer in accordance with Kendall-McCreary9s criteria. All ROM measurements were performed 3 times and mean values of 3 measurements were saved for data analysis. The relationships between kinesiophobia degrees and active &amp; passive flexion of the knee joint were analyzed by using Spearman9s Correlation test. <h3>Results</h3> There was a strong negative relationship between the kinesiophobia degrees and active (r=-0.881, p&lt;0.001) &amp; passive (r=-0.887, p&lt;0.001) ROM degrees of knee flexion. <h3>Conclusions</h3> One of the important aims of the treatment following ACL reconstruction is regaining functional level before injury and providing an early return to sports without any movement limitation. The results of this study revealed that presence of kinesiophobia at early stage influenced active and passive range of motion of knee joint negatively. Assessment of the kinesiophobia at early stage in ACL reconstructions could make a significant contribution to rehabilitation process in terms of achieving projected ranges of motions sooner in clinical settings. <h3>References</h3> Peter J. Millett, MD, MSc. Sports Medicine and Orthopaedic Surgery. ACL Reconstruction Rehabilitation Protocol. [Accessed 2016 January 30] Available from: http://drmillett.com/wp-content/uploads/2014/03/acl-rehab-protocol.pdf Kvist, J., Ek, A., Sporrstedt, K., &amp; Good, L. (2005). Fear of re-injury: a hindrance for returning to sports after anterior cruciate ligament reconstruction. Knee surgery, sports traumatology, arthroscopy, 13(5), 393–397. <h3>Disclosure of Interest</h3> None declared
Clinical and Biological Features of 43 Acute Megakaryoblastic Leukemia (AMKL) in Children: A Comparison of Down Syndrome-AMKL and De Novo AMKL.
Authors: Asahito Hama, Hiroshi Yagasaki, Koji Kato, Kimikazu Matsumoto, Keizo Horibe, Kazuko Kudo, Seiji Kojima
Journal: Blood (2005)
PWE-053 Multicentre European Study of Double Balloon Enteroscopy in Patients with Cardiovascular Disease: A Relationship Without Heartbreak?
Authors: H-L Ching, F Branchi, DE Yung, A Koulaouzidis, J Plevris, L Elli, DS Sanders, R Sidhu
Journal: Gut (2016)

<h3>Introduction</h3> Double balloon enteroscopy (DBE) is a relatively invasive and lengthy procedure necessitating careful consideration of patients’ comorbidities. We aim to assess the safety of DBE in patients with cardiovascular disease (CVD). <h3>Methods</h3> Between June 2006 and January 2016, 568 consecutive patients undergoing DBE were reviewed across 3 teaching hospitals in the UK and Italy. Demographic and clinical data were collected and patients were categorised by age (elderly: ≥70 years and young: &lt;70 years) and the presence or absence of CVD. Comparisons were made of diagnostic and therapeutic yields and complications rates. <h3>Results</h3> CVD was present in 185 patients (mean age 70±9.7, 51% male) who underwent DBE for iron deficiency anaemia (54%) overt gastrointestinal bleeding (25%), suspected Crohn’s disease (10%), small bowel strictures (6%) and suspected coeliac disease complications (4%). CVD (elderly vs young) included ischaemic heart disease (59% vs 68%, p = 0.2), valve replacement (23% vs 16%, p = 0.3), atrial fibrillation (31% vs 11%, <b>p &lt; 0.05</b>) and congestive cardiac failure (21% vs 8.5%, <b>p &lt; 0.05</b>). The 2 groups (elderly vs young) had similar propofol requirements (1320 mg vs 999 mg, p = 0.5), but midazolam (4 mg vs 5.5 mg, <b>p &lt; 0.05</b>) and fentanyl (36.5 mcg vs 75 mcg, <b>p &lt; 0.05</b>) use was less in the elderly. The most common abnormalities (elderly vs young) were ulcers (5.5% vs 10%, p = 0.4), strictures (3% vs 3%, p = 1.0), tumours (2% vs 7%, p = 0.2) and angioectasias (43% vs 27%, <b>p &lt; 0.05</b>). Diagnostic yield (67% vs 64%, p = 0.8) and complication rates (5.5% vs 2%, p = 0.3) were comparable. However, therapeutic yield was higher in the elderly (50.5% vs 33%, <b>p &lt; 0.05</b>). All CVD patients were compared to 383 patients without CVD (mean age 50±14.1, 44% male). Diagnostic yield was higher in those with CVD compared to those without (65% vs 50%, p &lt; 0.05), as was therapeutic yield (42% vs 17%, p &lt; 0.05). Irrespective of age, angioectasias were commoner in patients with CVD compared to those without (34.6% vs. 8.4%, p &lt; 0.05). The difference seen in complications between both groups was not significant (2.7% vs 0.8%, p = 0.12). Complications seen in the CVD group included 2 cases of systemic infections, 2 cases of respiratory compromise and 1 case of myocardial infarction. <h3>Conclusion</h3> We report the first multicentre study attesting the safety of patients with CVD undergoing DBE. Moreover, patients with CVD have higher diagnostic and therapeutic yield at DBE and thus with careful selection, these patients are most likely to benefit from the procedure. <h3>Disclosure of Interest</h3> None Declared
Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study
Authors: Amelia A Langston, Sujatha Murali, Stephanie McMillan, Leonard T. Heffner, Sagar Lonial, Edmund K. Waller, Christopher R. Flowers, Jonathan Kaufman, Morgan L. McLemore, Rajni Sinha, Mary J Lechowicz, H. Jean Khoury, Elliott F. Winton
Journal: Blood (2008)
Analysis of Survival, AML Transformation, and Transfusion Independence in Patients with High-Risk Myelodysplastic Syndromes (MDS) Receiving Azacitidine Determined Using a Prognostic Model.
Authors: Lewis R. Silverman, David R. McKenzie, Bercedis L. Peterson, Erin P. Demakos, James F. Holland, Richard R. Larson
Journal: Blood (2005)
PTU-142 A Cost-Effectiveness Analysis for Radiofrequency Ablation (RFA) in The Treatment of Patients with Barrett’s Oeosphagus Related Neoplasia in the United Kingdom
Authors: A Filby, M Taylor, G Lipman, R Haidry
Journal: Gut (2016)

<h3>Introduction</h3> Barrett’s oesophagus (BE) is the precursor lesion to osophageal adenocarcinoma (OAC) which carries a poor 5 year survival. BE progresses in patients through a metaplasia, dysplasia to cancer sequence. There is now consensus from worldwide societies to target the disease when there is dysplasia as these patients will develop invasive cancer in up to 50% of cases if left untreated. Treatment is now firmly established as minimally invasive endoscopic therapy with a combination of endoscopic resection for visible dysplasia surgery with oesophagectomy which can carry a significant mortality and morbidity. The aim of this analysis was to evaluate the cost-effectiveness of treating patients with HGD arising in BE with endoscopic therapy compared with surveillance alone in the UK. <h3>Methods</h3> A cost-effectiveness model was developed from an NHS perspective. The model structure consisted of a decision tree and a modified Markov model. The model considers a cohort of HGD patients and takes a lifetime time horizon. Patients move through the health states in the model (no dysplasia, low-grade dysplasia, HGD and OAC) based on natural history data (including progression and regression). HGD patients in the treatment arm are treated with RFA (plus EMR in a proportion of cases), LGD patients receive surveillance only. When patients are successfully treated with RFA they move to the ‘no dysplasia’ health state in the model and can progress again in the future. If treatment is not successful, the patient remains in the same health state in which they started treatment. In the comparator arm, all patients receive surveillance only. In both arms, when patients progress to OAC, patients are treated with oesophagectomy. Treatment with oesophagectomy can result in treatment success or death. The model inputs were derived from published literature, clinical expert opinion and standard cost sources. <h3>Results</h3> The results estimated that, at a time horizon of 45 years, providing HGD patients endoscopic treatment with RFA compared to endoscopic surveillance until cancer developed resulted in additional costs of £3,939. Patients benefitted from additional quality-adjusted life years (QALYs) of 0.954 per patient. The incremental-cost effectiveness ratio is £4,128. This would be considered cost-effective using the threshold of £20,000 to £30,000 used by NICE. <h3>Conclusion</h3> The economic model estimates that treating patients with BE related HGD with endoscopic treatment and RFA would be a cost efficient use of NHS resources and endorses the view of the British Society Of Gastroenterology advising this is as the standard of care in these patients. <h3>Disclosure of Interest</h3> A. Filby Consultant for: Medtronic, M. Taylor Consultant for: Medtronic, G. Lipman: None Declared, R. Haidry: None Declared
THU0600 Patients' Perception and Satisfaction of Waiting Time at Medical Outpatients
Authors: R. Magro, J. Aquilina
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patient satisfaction is an important determinant of health care quality. Decreasing waiting time is imperative in achieving patient satisfaction. <h3>Objectives</h3> The aim of this study was to determine the mean waiting time at medical outpatients and to assess waiting time satisfaction. A further aim was to identify factors that affect the patients9 perceived waiting time. <h3>Methods</h3> Data was collected through questionnaire responses from 190 patients attending medical outpatients between 20th March and 9th April 2013. This included demographic data, waiting time and service satisfaction, expected and perceived waiting time, level of boredom and comfort while waiting. Moreover the actual waiting time was noted by the observer. The relationship between expected and perceived waiting time; and between actual and perceived waiting time were in turn analyzed using scatter plots and correlation coefficients. Approval to carry out this study was obtained from the University Research and Ethics Committee. <h3>Results</h3> The participants had a mean age of 53 (range 19 to 86), of which 59% were females. On a 10-point Likert scale, the mean waiting time satisfaction was 7.1, while the mean service satisfaction was 9.3. The mean expected waiting time was 65 minutes and the mean perceived waiting time was 55 minutes. The mean actual waiting time was 51 minutes.This study revealed that as perceived waiting time increased, patient satisfaction tended to decrease consistently and significantly <i>(p</i>&lt;0.001). On the other hand, regression analysis revealed that perceived waiting time has a positive and significant linear relationship with the actual waiting time (<i>p</i>&lt;0.001) and the boredom levels of patients (<i>p</i>&lt;0.001). Patients seated comfortably had a significantly lower perceived waiting time that those who were not (<i>p</i>&lt;0.001). Perceived waiting time was not influenced by whether the patient was accompanied (<i>p</i>=0.313) or being seen for the first time (<i>p</i>=0.712). The patients reported that the provision of free tea or coffee, magazines or television, could help reduce boredom and divert their attention, thus reducing perceived waiting time and in turn enhancing satisfaction. 11% (21 patients) suggested that the operation of free wireless internet in the waiting areas would also reduce the level of their boredom during their wait. <h3>Conclusions</h3> Overall service satisfaction was extremely positive, while waiting time satisfaction was moderate. Although reducing the actual waiting time may be difficult, altering patients9 perceived waiting time may be beneficial to increase their satisfaction. This could be done by increasing their comfort and decreasing their boredom while waiting. <h3>Disclosure of Interest</h3> None declared
PWE-025 Serum Calprotectin – A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases
Authors: R Kalla, NA Kennedy, NT Ventham, R Boyapati, AT Adams, E Nimmo, M Visconti, H Drummond, GT Ho, R Pattenden, DC Wilson, J Satsangi
Journal: Gut (2016)

<h3>Introduction</h3> There is an unmet need for novel blood based biomarkers that offer timely and accurate diagnostic and prognostic testing in Inflammatory Bowel Diseases (IBD). We aimed to investigate the diagnostic and prognostic utility of serum calprotectin (SC) in IBD <h3>Methods</h3> A total of 156 patients (82 IBD and 74 non-IBD) were sampled within 90 days from diagnosis (median 0 days; IQR 0–7). A multibiomarker diagnostic and prognostic model was derived using multivariable logistic regression analysis. Treatment escalation was defined as the need for escalation and establishment of 2 or more immunomodulatory therapies and/or surgery for disease flare after initial induction of disease remission (criteria previously used by Lee et al) (1). Cox proportional hazards model was derived to assess the contribution of each variable to disease outcomes <h3>Results</h3> SC correlated strongly with current biomarkers including CRP (rho = 0.60, p = 1.4x10<sup>−16</sup>) faecal calprotectin (FC) (rho = 0.51, p = 1.6x10<sup>−4</sup>). Paired FC was available within 30 days (median 0 days, IQR: -4 to5 days) of SC in 50 patients (IBD n = 30, non-IBD n = 20).The area under receiver operating characteristic discriminating IBD from controls was similar for FC and SC(0.95, 95% CI 0.87–1.00 and 0.89, 95%CI 0.81–0.98 respectively;p = 0.36). SC was the strongest individual predictor of IBD diagnosis (odds ratio (OR): 12.33 (95% CI 4.48–38.33, p = 3.5×10<sup>−6</sup>) compared with other markers (CRP: OR 4.44, CI 1.58–12.90; albumin: OR 5.65, CI 1.98–17.16). At follow up (median 342 days; IQR: 88–563),a total of 1 (2%), 16 (47%),23 (51%) patients required treatment escalation in the IBDU, CD and UC group respectively.SC predicted treatment escalation and/or surgery in IBD (HR 2.4, 95% CI: 1.1–4.9), in particular CD (HR 4.1, 95% CI 1.1–14.7). A model incorporating SC, CRP and albumin has a positive likelihood ratio of 20.03 for IBD.At 1 year, our prognostic model can predict treatment escalation in IBD in 65% of cases (95% CI: 43–79%) and 80% (95% CI: 31–94%) in CD if 2 or more blood marker criteria are met. <h3>Conclusion</h3> Sampling faeces can be a hurdle for patients and some individuals can decline FC testing. These factors impact on the practical utility of FC.SC shows promise as a diagnostic and prognostic biomarker in IBD. Our findings warrant further exploration and validation within large multicentre cohorts. <h3>Reference</h3> 1 Lee JC, <i>et al</i>. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. <i>J Clin Invest</i> 2011;<b>121</b>:4170–9. <h3>Disclosure of Interest</h3> None Declared
AB0678 A Comparison of Depression and Anxiety Levels in Patients with Non-Radiographic Axial Spondyloarthropathy with Those in Patients with Ankylosing Spondylitis: Table 1.
Authors: D. Solmaz, E. Barisan, T. Yildirim, S. Akar
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The concept of axial spondyloarthropathy (SpA) recently recommended by the ASAS includes patients comprising the early and late stages of the disease. This concept also includes patients not meeting the criteria for ankylosing spondylitis (AS) but classified as non-radiographic SpA on the basis of chronic lumbar back pain and other characteristics of SpA. Although this group is more heterogeneous and distinct from AS in terms of some characteristics, it still has a similar burden in terms of disease activity. Psychiatric symptoms can often be seen in patients during the course of AS. Depressive symptoms are seen at levels of 27.4–55.5% and anxiety symptoms at levels of 19.5–60.9%. Few studies have investigated this situation in the non-radiographic SpA group. <h3>Objectives</h3> To assess depression and anxiety levels in AS and non-radiographic SpA groups and to review potentially associated factors. <h3>Methods</h3> One hundred fifty-five (114 AS, 41 non-radiographic SpA) patients with axial SpA according to the ASAS definition were included in the study. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to assess activity, visual anolog scale (VAS) for spinal pain, the Bath Ankylosing Spondylitis Functional Index (BASFI) for functional capacity and the Ankylosing Spondylitis Quality of Life (ASQOL) for quality of life. The State-Trait Anxiety inventory (STAI), Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI) were used to determine psychiatric symptoms. <h3>Results</h3> The AS patient group (mean age 39±10.8, male 73.4%) was older than the non-radiographic SpA group (mean age 35±10.1, male 54.8%), and had a greater preponderance of males. No difference was determined between the two groups in terms of BASDAI, VAS spinal pain, ASQOL or BASFI scores. Psychiatric measurements were also similar between the AS and non-radiographic SpA groups. The STAI, BDI and BAI exhibited good correlated with BASDAI, BASFI, ASQOL and VAS spinal pain (Table). <h3>Conclusions</h3> Despite the presence of some clinical differences between the AS group and the non-radiographic SpA group, regarded as the early stage of the disease, the two group exhibit similar features in terms of psychiatric symptoms and disease activity. Psychiatric symptoms are closely associated with disease activity, functional capacity and quality of life. <h3>Disclosure of Interest</h3> None declared
Targeting the D Series Resolvin Receptor System for the Treatment of Osteoarthritis Pain
Authors: Junting Huang, James J. Burston, Li Li, Sadaf Ashraf, Paul I. Mapp, Andrew J. Bennett, Srinivasarao Ravipati, Petros Pousinis, David A. Barrett, Brigitte E. Scammell, Victoria Chapman
Journal: Arthritis & Rheumatology (2016)

Objective Pain is a major symptom of osteoarthritis (OA); currently available analgesics either do not provide adequate pain relief or are associated with serious side effects. The aim of this study was to investigate the therapeutic potential of targeting the resolvin receptor system to modify OA pain and pathology. Methods Gene expression of 2 resolvin receptors (ALX and ChemR23) was quantified in synovium and medial tibial plateau specimens obtained from patients with OA at the time of joint replacement surgery. Two models of OA joint pain were used for the mechanistic studies. Gene expression in the joint and central nervous system was quantified. The effects of exogenous administration of the D series resolvin precursor 17(R)‐hydroxy‐docosahexaenoic acid (17[R]‐HDoHE) on pain behavior, joint pathology, spinal microglia, and astroglyosis were quantified. Plasma levels of relevant lipids, resolvin D2, 17(R)‐HDoHE, and arachidonic acid, were determined in rats, using liquid chromatography tandem mass spectrometry. Results There was a positive correlation between resolvin receptor and interleukin‐6 (IL‐6) expression in human OA synovial and medial tibial plateau tissue. In rats, synovial expression of ALX was positively correlated with expression of IL‐1β, tumor necrosis factor, and cyclooxygenase 2. Treatment with 17(R)‐HDoHE reversed established pain behavior (but not joint pathology) in 2 models of OA pain. This was associated with a significant elevation in the plasma levels of resolvin D2 and a significant reduction in astrogliosis in the spinal cord in the monosodium iodoacetate–induced OA rat model. Conclusion Our preclinical data demonstrate the robust analgesic effects of activation of the D series resolvin pathways in 2 different animal models of OA. Our data support a predominant central mechanism of action in clinically relevant models of OA pain.
Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities
Authors: Sao Jiralerspong, Pamela J. Goodwin
Journal: Journal of Clinical Oncology (2016)

Purpose To summarize the evidence of an association between obesity and breast cancer prognosis. Methods We reviewed the literature regarding overweight and obesity and breast cancer survival outcomes, overall and with regard to breast cancer subtypes, breast cancer therapies, biologic mechanisms, and possible interventions. We summarize our findings and provide clinical management recommendations. Results Obesity is associated with a 35% to 40% increased risk of breast cancer recurrence and death and therefore poorer survival outcomes. This is most clearly established for estrogen receptor–positive breast cancer, with the relationship in triple-negative and human epidermal growth factor receptor 2–positive subtypes less well established. A range of biologic mechanisms that may underlie this association has been identified. Weight loss and lifestyle interventions, as well as metformin and other obesity-targeted therapies, are promising avenues that require further study. Conclusion Obesity is associated with inferior survival in breast cancer. Understanding the nature and mechanisms of this effect provides an important opportunity for interventions to improve the diagnosis, treatment, and outcomes of obese patients with breast cancer.